Payment overview · 2025
General Payments
$349.92
14 reported records · 5 companies
Healthcare provider profile · identity verified
Dinesh U. Nayak, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANCHESTER, OH · NPI 1932102092
Verified facts
What the public records show
CMS Open Payments records show Dinesh U. Nayak, MD received $349.92 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.42 | 55.3% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $76.75 | 21.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.19 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.24 | 8.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.32 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.92 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.03 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $77.39 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $76.75 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 45 |
| Gabapentin | Gabapentin | 261 | 57 |
| Metformin Hcl | Metformin Hcl | 222 | 39 |
| Losartan Potassium | Losartan Potassium | 214 | 40 |
| Prednisone | Prednisone | 203 | 94 |
| Lisinopril | Lisinopril | 192 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 28 |
| Montelukast Sodium | Montelukast Sodium | 184 | 43 |
| Omeprazole | Omeprazole | 176 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 157 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 26 |
| Potassium Chloride | Potassium Chloride | 146 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 131 | 31 |
| Furosemide | Furosemide | 125 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 30 |
| Glimepiride | Glimepiride | 110 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 17 |
| Cefdinir | Cefdinir | 82 | 53 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 74 | 38 |
| Mounjaro | Tirzepatide | 74 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 17 |
| Clonidine Hcl | Clonidine Hcl | 66 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 18 |
| Diazepam | Diazepam | 64 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 20 |
| Tramadol Hcl | Tramadol Hcl | 62 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 57 | 11 |
| Cephalexin | Cephalexin | 56 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 12 |
| Lovastatin | Lovastatin | 56 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Simvastatin | Simvastatin | 50 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | 20 |
| Dilt-Xr | Diltiazem Hcl | 47 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 11 |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 45 | 38 |
| Pentoxifylline | Pentoxifylline | 45 | suppressed |
| Alprazolam | Alprazolam | 42 | 14 |
| Celecoxib | Celecoxib | 42 | 12 |
| Zafirlukast | Zafirlukast | 40 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Theophylline | Theophylline Anhydrous | 38 | 21 |
| Digoxin | Digoxin | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | 14 |
| Topiramate | Topiramate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Nitroglycerin | Nitroglycerin | 31 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Clonazepam | Clonazepam | 25 | 11 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | 12 |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.92 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, TRELEGY ELLIPTA, VRAYLAR, Vest Therapy Und | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error